Samir H. Moussa

1.6k total citations
29 papers, 852 citations indexed

About

Samir H. Moussa is a scholar working on Molecular Medicine, Molecular Biology and Pharmacology. According to data from OpenAlex, Samir H. Moussa has authored 29 papers receiving a total of 852 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Medicine, 8 papers in Molecular Biology and 8 papers in Pharmacology. Recurrent topics in Samir H. Moussa's work include Antibiotic Resistance in Bacteria (17 papers), Antibiotic Use and Resistance (7 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Samir H. Moussa is often cited by papers focused on Antibiotic Resistance in Bacteria (17 papers), Antibiotic Use and Resistance (7 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Samir H. Moussa collaborates with scholars based in United States, Australia and Lebanon. Samir H. Moussa's co-authors include Alita A. Miller, Sarah M. McLeod, Adam B. Shapiro, Suzanne Walker, Thomas F. Durand-Réville, Ry Young, Michael S. Gilmore, Rubén Tommasi, Ramkumar Iyer and Timothy C. Meredith and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Genes & Development and SHILAP Revista de lepidopterología.

In The Last Decade

Samir H. Moussa

28 papers receiving 805 citations

Peers

Countries citing papers authored by Samir H. Moussa

Since Specialization

Citations

This map shows the geographic impact of Samir H. Moussa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samir H. Moussa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samir H. Moussa more than expected).

Fields of papers citing papers by Samir H. Moussa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samir H. Moussa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samir H. Moussa. The network helps show where Samir H. Moussa may publish in the future.

Co-authorship network of co-authors of Samir H. Moussa

This figure shows the co-authorship network connecting the top 25 collaborators of Samir H. Moussa. A scholar is included among the top collaborators of Samir H. Moussa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samir H. Moussa. Samir H. Moussa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Small molecule inhibitors of mannan-binding lectin-associated serine Proteases-2 and-3 2025 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Adam B. Shapiro, Samir H. Moussa, April Chen, Charles J. Eyermann, John P. O’Donnell, Alita A. Miller, (unknown)	0
2	Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial 2024 ·Open Forum Infectious Diseases ·Sarah M. McLeod, Alita A. Miller, Khurram Rana, David Altarac, Samir H. Moussa, Adam B. Shapiro	7
3	Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK) 2024 ·Antimicrobial Agents and Chemotherapy ·Alita A. Miller, Samir H. Moussa, Sarah M. McLeod	9
4	Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii 2023 ·Antimicrobial Agents and Chemotherapy ·Samir H. Moussa, Adam B. Shapiro, Sarah M. McLeod, Ramkumar Iyer, Nicole Carter, Yu-Kuo Tsai, L. Kristopher Siu, Alita A. Miller	23
5	2138. In Vitro Susceptibility of Recent Clinical Isolates of P. aeruginosa and Enterobacterales to Imipenem or Meropenem Alone or in Combination with Sulbactam-Durlobactam 2023 ·Open Forum Infectious Diseases ·Sarah M. McLeod, Nicole Carter, Samir H. Moussa, Alita A. Miller	1
6	In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam 2023 ·Open Forum Infectious Diseases ·(unknown), Laurie Grier, (unknown), (unknown), Mohammad Khursheed Alam, Samir H. Moussa, Jennifer Smith, Samuel L Aitken, Alexandre Malek	9
7	Digital transformation of accounting practices and behavior during COVID-19: MENA evidence 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Samir H. Moussa	6
8	Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam 2021 ·Frontiers in Microbiology ·Adam B. Shapiro, Samir H. Moussa, Sarah M. McLeod, Thomas F. Durand-Réville, Alita A. Miller	61
9	1073. Sulbactam-Durlobactam Has Potent Activity Against Multidrug-Resistant Acinetobacter baumannii Clinical Isolates From Thai Patients With Chronic Infections 2021 ·Open Forum Infectious Diseases ·Dhammika Leshan Wannigama, Paul G. Higgins, Cameron Hurst, Shuichi Abe, Parichart Hongsing, Sirirat Luk-in, (unknown), (unknown), (unknown), (unknown), Anthony Kicic, Tanittha Chatsuwan, Samir H. Moussa, Alita A. Miller	1
10	The Structural Basis of T4 Phage Lysis Control: DNA as the Signal for Lysis Inhibition 2020 ·Journal of Molecular Biology ·Inna V. Krieger, Vladimir A. Kuznetsov, Jeng-Yih Chang, Junjie Zhang, Samir H. Moussa, Ry Young, James C. Sacchettini	24
11	N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay 2020 ·Bioorganic & Medicinal Chemistry ·(unknown), Adam B. Shapiro, Janelle Comita-Prevoir, (unknown), Jing Zhang, Seth Ribe, April Chen, (unknown), Samir H. Moussa, Nicole Carter, Mark Sylvester, Jan Antoinette C. Romero, (unknown), M. Sacco, Yu Chen, John P. O’Donnell, Thomas F. Durand-Réville, Alita A. Miller, Rubén Tommasi	16
12	In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii- calcoaceticus Complex Isolates Collected Globally in 2016 and 2017 2020 ·Antimicrobial Agents and Chemotherapy ·Sarah M. McLeod, Samir H. Moussa, Meredith Hackel, Alita A. Miller	63
13	Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent 2019 ·mBio ·Melissa D. Barnes, Vijay Kumar, Christopher R. Bethel, Samir H. Moussa, John P. O’Donnell, Joseph Rutter, Caryn E. Good, Kristine M. Hujer, Andrea M. Hujer, Steve H. Marshall, Barry N. Kreiswirth, Sandra S. Richter, Philip N. Rather, Michael R. Jacobs, Krisztina M. Papp‐Wallace, Focco van den Akker, Robert A. Bonomo	95
14	Role of the Klebsiella pneumoniae TolC porin in antibiotic efflux 2018 ·Research in Microbiology ·Ramkumar Iyer, Samir H. Moussa, Rubén Tommasi, Alita A. Miller	11
15	Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii 2017 ·Antimicrobial Agents and Chemotherapy ·Sarah M. McLeod, Adam B. Shapiro, Samir H. Moussa, Michele Johnstone, Robert E. McLaughlin, Boudewijn L. M. de Jonge, Alita A. Miller	54
16	A new platform for ultra-high density Staphylococcus aureus transposon libraries 2015 ·BMC Genomics ·Marina Santiago, Leigh M. Matano, Samir H. Moussa, Michael S. Gilmore, Suzanne Walker, Timothy C. Meredith	71
17	A synthetic lethal approach for compound and target identification in Staphylococcus aureus 2015 ·Nature Chemical Biology ·Lincoln W. Pasquina, John P. Santa Maria, (unknown), Samir H. Moussa, Leigh M. Matano, Marina Santiago, Sara E. Martin, Wonsik Lee, Timothy C. Meredith, Suzanne Walker	59
18	Stable micron‐scale holes are a general feature of canonical holins 2013 ·Molecular Microbiology ·Christos G. Savva, (unknown), Samir H. Moussa, (unknown), Andreas Holzenburg, Ry Young	37
19	Protein determinants of phage T4 lysis inhibition 2012 ·Protein Science ·Samir H. Moussa, Vladimir A. Kuznetsov, Tram Anh T. Tran, James C. Sacchettini, Ry Young	33
20	Active Bax and Bak are functional holins 2011 ·Genes & Development ·Xiaming Pang, Samir H. Moussa, (unknown), Jeffrey L. Bose, Nicholas M. George, Casey M. Gries, Hernando López-Bertoni, Liqiang Zhang, Kenneth W. Bayles, Ry Young, Xu Luo	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact